New Move Free Advanced contains Uniflex and hyaluronic acid, "which make the product two times more effective in relieving joint pain compared to triple strength glucosamine and chondroitin alone," Schiff Nutrition International announces Jan. 25. Uniflex is a dual bioflavanoid antioxidant system, which protects against the breakdown of cartilage and joint tissues, and helps keep joints working better. The new SKU "works in as little as seven to 14 days, versus four to eight weeks for products containing glucosamine and chondroitin alone" the firm claims, and is backed by an independent study conducted in 2004. Move Free Advanced and Move Free Advanced Plus are available now at health, food, drug and mass merchandisers nationwide, Schiff says...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.
